Zantac 75 sales reach $46 mil. in second quarter; OTC Tagamet sales $23 mil. worldwide.
This article was originally published in The Tan Sheet
Executive Summary
ZANTAC 75 SECOND QUARTER SALES REACH $46 MIL. in the U.S., and the heartburn remedy has established a "strong number two position" in the OTC H2 antagonist market with a 35% share, Warner-Lambert said July 22. J&J/Merck's Pepcid AC continues as the category leader. Zantac 75 was introduced in the U.S. in late April 1996, and the company recently announced plans to launch the product in Canada, Australia and other European countries ("The Tan Sheet" April 21, p. 10)